The mechanism underlying the synergistic effect of the BET inhibitor AZD5153 with the PARP inhibitor olaparib (NCT03205176) in the treatment of ovarian cancer is that AZD5153 enhances the sensitivity of cells to olaparib and destabilizes genetic material by downregulating PTEN expression, thereby reversing acquired resistance.175 Through PAX5 and B-cell antigen receptor mechanisms essential for ABC DLBCL, AZD5153 enhances the efficacy of the Bruton tyrosine kinase inhibitor acalabrutinib in ABC DLBCL cell lines (NCT03527147).176. Here, DNER is linked to ovarian carcinoma.